Evidence map›Paper›PMID 39141383›Full record

ArticleJAMA network open2024

Depressive Symptoms in Adolescence and Young Adulthood.

Katherine M Keyes, Noah T Kreski, Megan E Patrick

Abstract read
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katherine M KeyesDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Noah T KreskiDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York.
Megan E PatrickInstitute for Social Research, University of Michigan, Ann Arbor.

Funding

Monitoring the Future: Drug Use & Lifestyles of American Youth (Supp1: Nicotine Pouch and E-cigarette Use Among US Adolescents: National Estimates of Brand Use and Flavor Preferences)R01DA001411 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Richard A Miech · 1985 to 2026
$144.9M
Monitoring the Future: A Cohort-Sequential Panel Study of Drug Use, Ages 19-65 - Diversity Supplement (Solberg)R01DA016575 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Megan E. Patrick · 2003 to 2026
$44.6M
As adolescent substance use declines, internalizing symptoms increase: identifying high-risk substance using groups and the role of social media, parental supervision, and unsupervised timeR01DA048853 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI KEYES, KATHERINE M. · 2019 to 2023
$2.0M
NIDA NIH HHS R01 DA001411NIDA NIH HHS R01 DA016575NIDA NIH HHS R01 DA048853
6 · The paper itself

Abstract

Importance: Depressive symptoms have increased among US adolescents since 2010. It remains unclear as to what extent this increase will persist into young adulthood, potentially turning the youth mental health crisis into a young adult mental health crisis. Objective: To test the association between birth cohort and adolescent depressive symptoms at ages 18, 19 to 20, and 21 to 22 years and changes in these symptoms by cohort. Design, Setting, and Participants: This panel cohort study analyzed data from the Monitoring the Future longitudinal survey from 1990 to 2019, including birth cohorts from 1972 to 2001. Survey respondents were recruited from US high schools in 12th grade and were approximately aged 18 years (at baseline) through age 21 to 22 years (during mail and web follow-up). Data analysis was conducted from April to October 2023. Exposure: Depressive symptoms score (>12 vs ≤12, with >12 representing top-decile scores) on a scale examining affective items (eg, "Life often seems meaningless"). Main Outcomes and Measures: High (vs lower) depressive symptoms at ages 19 to 20 years and 21 to 22 years. Results: The 36 552 respondents included 18 597 females (50.5%), and most reported having a parent who graduated from college (44.8%). Among females, 19.1% (95% CI, 16.7%-21.4%) of the most recent birth cohort (born: 1997-2001) had high depressive symptoms at age 18 years, higher than any previous birth cohort. While prevalence declined by age 21 to 22 years, it remained higher than previous cohorts at that age. Among males, 13.4% (95% CI, 11.2%-15.6%) of the most recent birth cohort had high depressive symptoms at age 18 years, and prevalence increased through young adulthood. Males with high baseline depressive symptoms had 10.24 (95% CI, 7.01-14.97) times the odds of symptoms at age 19 to 20 years and 6.20 (95% CI, 3.93-9.78) times the odds of symptoms at age 21 to 22 years. Females with high baseline depressive symptoms had 9.16 (95% CI, 6.57-12.76) times the odds of symptoms at age 19 to 20 years and 7.28 (95% CI, 4.92-10.78) times the odds of symptoms at age 21 to 22 years. The magnitude of the associations did not vary over time. Population attributable fractions indicated that the total proportion of young adult symptoms associated with depressive symptoms at age 18 years among females has increased; in the most recent birth cohort, 55.25% (95% CI, 38.11%-65.13%) of depressive symptoms at age 21 to 22 years were associated with symptoms at age 18 years. Conclusions and Relevance: This panel cohort study found that increases in depressive symptoms in adolescence persisted into young adulthood, suggesting the need for primary prevention and mental health resources during the adolescent years.

Indexed as

DepressionAdolescentAdultCohort StudiesFemaleHumansLongitudinal StudiesMalePrevalenceUnited StatesYoung Adult

Identifiers

PMID39141383
PMCPMC11325205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.